MNPR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
7.5M
+12.4%
6.6M
+27.2%
5.2M
-15.1%
6.2M
+50.4%
4.1M
R&D
4.4M
-6.9%
4.8M
+36.7%
3.5M
-11.5%
3.9M
+52.2%
2.6M
SG&A
3.0M
+61.4%
1.9M
+8.0%
1.7M
-21.5%
2.2M
+47.3%
1.5M
Operating Income
-7467845
-12.4%
-6644663
-27.2%
-5225253
+15.1%
-6155228
-50.4%
-4093074
EBITDA
-7467845
-12.4%
-6644663
-27.2%
-5225253
+15.1%
-6155228
-50.4%
-4093074
Net Income
-6196475
-16.6%
-5313300
-36.5%
-3893050
+25.1%
-5200794
-51.3%
-3437601
EPS (Basic)
$-0.72
-16.1%
$-0.62
-34.8%
$-0.46
+24.6%
$-0.61
-27.1%
$-0.48
EPS (Diluted)
$-0.72
-16.1%
$-0.62
-34.8%
$-0.46
+24.6%
$-0.61
-27.1%
$-0.48
Shares (Diluted)
8.6M
+0.2%
8.5M
+0.1%
8.5M
+0.0%
8.5M
+19.8%
7.1M
Monopar Therapeutics (MNPR) — Financials